ClinicalTrials.gg
RecruitingNCT06047782FIBROSIS-MRIUpdated Oct 26, 2026

Impact of Atrial Fibrosis Surface Area on the Occurrence of Atrial Fibrillation in Patients With Ischemic Stroke of Undetermined Origin: a Prospective Cardiac MRI Pilot Study.

An interventional study of Cardiac MRI (with contrast agent) in Stroke and Implantation of an Implantable Cardiac Monitor, sponsored by Centre Hospitalier Universitaire Dijon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Centre Hospitalier Universitaire Dijon · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.
Updated Oct 26, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
157
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Stroke by Centre Hospitalier Universitaire Dijon — 3 open to participants now, 3 under way, none of them phase 3. Stroke · Centre Hospitalier Universitaire Dijon.

Started
2024
the only one that year
No phase
7 of 12
2 open now
Registered
12th of 12
by date

Among the 12 studies in Stroke by Centre Hospitalier Universitaire Dijon, this one is the only one that started in 2024, is one of 7 with no phase, and was the 12th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

3 of the 12 studies in Stroke by Centre Hospitalier Universitaire Dijon are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Stroke by Centre Hospitalier Universitaire Dijon, or all of them as a file.
02

Study summary

Atrial fibrillation is a cardiac arrhythmia most often originating in the left atrium, causing anarchic electrical activity and thus a loss of atrial contraction. This increases the risk of stroke through clot formation in the atrium, but also of heart failure. Atrial fibrillation is a major cause of stroke, accounting for more than 25% of all strokes. In addition, a quarter of ischemic strokes remain without an obvious cause at the end of hospitalization, and it is recommended that atrial fibrillation be detected intensively with long-term heart rhythm recording. Implantable loop recorders can detect 30% of atrial fibrillation cases over the 3-year battery life of these devices, after a stroke of undetermined origin. However, these devices require a small operation to implant them under the skin, and they are expensive.

The hypothesis of this study is that MRI imaging of the left atrium would enable better selection of patients to receive an implantable loop recorder. MRI can quantify the proportion of the left atrium with scar tissue, which is likely to favour the onset of atrial fibrillation. If the results confirm this hypothesis, the number of patients requiring an implantable loop recorder could be reduced, and perhaps an anticoagulation strategy based on MRI data could be introduced.

In addition to the usual follow-up by cardiologists and neurologists, participation in this study involves a cardiac MRI (with contrast agent) within 3 months of the stroke.

03

Conditions studied

  • Stroke
  • Implantation of an Implantable Cardiac Monitor

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient who has provided free, written and
  • Patient of legal age
  • Patient with cryptogenic ischemic stroke within 30 days of inclusion, documented by brain imaging (cerebral angioscan or cerebral MRI)
  • Patients scheduled for implantable loop recorder implantation within 3 months of ischemic stroke in search of silent AF:

    • cryptogenic ischemic stroke or stroke with probable cardioembolic cause
    • no history of atrial fibrillation
    • no long-term anticoagulant therapy
    • with >12 months

Exclusion criteria

Exclusion Criteria:

  • Person not affiliated to national health insurance
  • Person under legal protection (curatorship, guardianship)
  • Person under court order
  • Pregnant, parturient or breast-feeding
  • Adult unable to give consent
  • Patient diagnosed with AF during stroke assessment
  • Patient with a to MRI or gadolinium injection:

    • Severe renal impairment (\<30ml/min Cockroft clearance due to gadolinium injection)
    • Claustrophobia / contraindication to MRI (metal implant not MRI compatible)
    • History of to gadoteric acid or gadolinium-based contrast agents, and to meglumine
    • Uncontrolled asthma
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
157 participants (estimated)

Interventions

  • OtherCardiac MRI (with contrast agent)

    Cardiac MRI with contrast agent

06

What researchers measure

Primary outcomes

  1. Episode of atrial fibrillation (AF) lasting more than 30 seconds on the implantable loop recorder

    Time frame: at 3-year follow-up

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2031, 84 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 84 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Jan 2030 → Jan 2031 and completion Jan 2030 → Jan 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2023
First posted
Sep 21, 2023
StartActual
Jan 31, 2024
Primary completionEst.
Jan 2031was Jan 2030
CompletionEst.
Jan 2031was Jan 2030
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 2030→Jan 2031
Oct 26, 2026
Study completion
Jan 2030→Jan 2031
Oct 26, 2026
Enrollment
100→157
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Primary completion Jan 2030→Jan 2031
    Study completion Jan 2030→Jan 2031
    Enrollment 100→157
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06047782
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Jan 31, 2024
Primary completion
Jan 2031 (estimated)
Completion
Jan 2031 (estimated)
Last update
Oct 26, 2026

Study contacts

Charles GUENANCIA
Contact
charles.guenancia@chu-dijon.fr
0380295623

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion